Product Information
SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR is a brand biologic product labeled by Teva Pharmaceuticals USA Inc., priced at $499.1194 per EA under NDC 51759040202. Its NADAC has been published 76 times since Apr 23, 2025.
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
51759040202
Classification
Brand Biologic
Dosage Form
KIT
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA761299On Market Since
5/20/2024
Price Statistics
The NADAC for SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR has been published 76 times since Apr 23, 2025, and over the history we have for it it has risen 3.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $499.1194 per EA |
|---|---|
| All-time high | $499.1194 (Sep 30, 2026) |
| All-time low | $479.2713 (Jul 23, 2025) |
| 52-week high | $499.1194 |
| 52-week low | $479.7792 |
| Median price | $485.9995 |
| Average price | $486.3388 |
| Largest weekly change | +1.1% (Sep 23, 2026) |
| Weeks tracked | 76 |
| Tracking since | Apr 23, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
adalimumab-ryvk market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR?
The current National Average Drug Acquisition Cost (NADAC) for SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR, manufactured by Teva Pharmaceuticals USA Inc., is $499.1194 per EA (NDC 51759040202), effective Sep 30, 2026.
How has the price of SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR changed over time?
Over the history we have for it, the NADAC for SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR has risen 3.3%. It has been tracked across 76 weekly CMS publications since Apr 23, 2025.
What are the highest and lowest recorded NADAC prices for SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR?
Since Apr 23, 2025, the NADAC for SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR has ranged from a low of $479.2713 (Jul 23, 2025) to a high of $499.1194 (Sep 30, 2026), with a median of $485.9995 per EA.
Are there cheaper alternatives to SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR in a comparable dosage form, but none are currently priced below it.
Who manufactures SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR?
SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR (NDC 51759040202) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a brand biologic product.